ABEC Launches ATB™-2100 Bioreactor for Advanced Therapy Manufacturing

BETHLEHEM, Pa., Nov. 5, 2026 /CourierPR/ -- ABEC, a global leader in engineered solutions and services for biopharmaceutical manufacturing, has launched the ATB™-2100 Advanced Therapy Bioreactor, marking a significant advancement in the field of cell and gene therapy manufacturing. This new technology aims to address the industry's growing need for scalable, reproducible, and automated manufacturing processes.

The ATB™-2100 represents a novel approach to advanced therapy processing, combining unprecedented process control and scalability in a fully-closed and automated platform. It supports cell expansion from preclinical development through commercial manufacturing, making it suitable for the most challenging cell and gene therapy applications. The platform has successfully demonstrated the expansion of T-cells, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and other emerging modalities.

At the heart of the ATB™-2100 is ABEC's proprietary network of hollow-fiber perfusion membranes. These membranes continuously deliver nutrients and gases throughout the culture environment while removing metabolic waste. The system emulates the human circulatory system with a diffusion-based, low-shear environment that is ideal for cell growth. This unique design enables exceptionally high cell densities and viabilities, as cells are not exposed to the stresses commonly associated with other platforms.

Unlike other cell expansion technologies that require process redevelopment during scale-up, the ATB™-2100 maintains a consistent membrane surface-area-to-volume ratio across bioreactor volumes from 200mL to 10L. This feature enables direct translation of process conditions from early-stage development through commercial production, significantly reducing development timelines, minimizing risk during technology transfer, and accelerating time to market.

With more than 50 years of innovation, ABEC combines bioprocess equipment expertise, engineering, manufacturing, automation, and services to support the development and commercialization of life-changing therapies. The ATB™-2100 is a testament to ABEC's commitment to advancing the biopharmaceutical industry and enabling the successful manufacturing of advanced therapies.